Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma

•Adoption of neoadjuvant chemotherapy among high-volume facilities varies.•Patients managed at low-adopting facilities experience higher surgical morbidity.•Inappropriate selection of patients for primary cytoreductive surgery is associated with worse oncologic outcomes.